These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 29856864)

  • 1. Evaluation of different analysis pipelines for the detection of HIV-1 minority resistant variants.
    Perrier M; Désiré N; Storto A; Todesco E; Rodriguez C; Bertine M; Le Hingrat Q; Visseaux B; Calvez V; Descamps D; Marcelin AG; Charpentier C
    PLoS One; 2018; 13(6):e0198334. PubMed ID: 29856864
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of Automatic Analysis of Ultradeep Pyrosequencing Raw Data to Determine Percentages of HIV Resistance Mutations in Patients Followed-Up in Hospital.
    Bellecave P; Recordon-Pinson P; Fleury H
    AIDS Res Hum Retroviruses; 2016 Jan; 32(1):85-92. PubMed ID: 26529549
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Highly frequent HIV-1 minority resistant variants at baseline of the ANRS 139 TRIO trial had a limited impact on virological response.
    Charpentier C; Lee GQ; Rodriguez C; Visseaux B; Storto A; Fagard C; Molina JM; Katlama C; Yazdanpanah Y; Harrigan PR; Descamps D
    J Antimicrob Chemother; 2015 Jul; 70(7):2090-6. PubMed ID: 25755001
    [TBL] [Abstract][Full Text] [Related]  

  • 4. RNA and DNA Sanger sequencing versus next-generation sequencing for HIV-1 drug resistance testing in treatment-naive patients.
    Alidjinou EK; Deldalle J; Hallaert C; Robineau O; Ajana F; Choisy P; Hober D; Bocket L
    J Antimicrob Chemother; 2017 Oct; 72(10):2823-2830. PubMed ID: 29091197
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cross-clade simultaneous HIV drug resistance genotyping for reverse transcriptase, protease, and integrase inhibitor mutations by Illumina MiSeq.
    Dudley DM; Bailey AL; Mehta SH; Hughes AL; Kirk GD; Westergaard RP; O'Connor DH
    Retrovirology; 2014 Dec; 11():122. PubMed ID: 25533166
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Unravelling the dynamics of selection of multiresistant variants to integrase inhibitors in an HIV-1-infected child using ultra-deep sequencing.
    Stefic K; Salmona M; Capitao M; Splittgerber M; Maakaroun-Vermesse Z; Néré ML; Bernard L; Chaix ML; Barin F; Delaugerre C
    J Antimicrob Chemother; 2017 Mar; 72(3):850-854. PubMed ID: 27999055
    [TBL] [Abstract][Full Text] [Related]  

  • 7. HIV-1 Protease, Reverse Transcriptase, and Integrase Variation.
    Rhee SY; Sankaran K; Varghese V; Winters MA; Hurt CB; Eron JJ; Parkin N; Holmes SP; Holodniy M; Shafer RW
    J Virol; 2016 Jul; 90(13):6058-6070. PubMed ID: 27099321
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of an
    Tzou PL; Ariyaratne P; Varghese V; Lee C; Rakhmanaliev E; Villy C; Yee M; Tan K; Michel G; Pinsky BA; Shafer RW
    J Clin Microbiol; 2018 Jun; 56(6):. PubMed ID: 29618499
    [TBL] [Abstract][Full Text] [Related]  

  • 9. HIV-1 DNA ultra-deep sequencing analysis at initiation of the dual therapy dolutegravir + lamivudine in the maintenance DOLULAM pilot study.
    Charpentier C; Montes B; Perrier M; Meftah N; Reynes J
    J Antimicrob Chemother; 2017 Oct; 72(10):2831-2836. PubMed ID: 29091218
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Differences in the integrase and reverse transcriptase transmitted resistance patterns in Northern Poland.
    Parczewski M; Leszczyszyn-Pynka M; Urbańska A
    Infect Genet Evol; 2017 Apr; 49():122-129. PubMed ID: 28017912
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An international multicenter study on HIV-1 drug resistance testing by 454 ultra-deep pyrosequencing.
    Simen BB; Braverman MS; Abbate I; Aerssens J; Bidet Y; Bouchez O; Gabriel C; Izopet J; Kessler HH; Stelzl E; Di Giallonardo F; Schlapbach R; Radonic A; Paredes R; Recordon-Pinson P; Sakwa J; St John EP; Schmitz-Agheguian GG; Metzner KJ; Däumer MP;
    J Virol Methods; 2014 Aug; 204():31-7. PubMed ID: 24731928
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Investigation of drug resistance against protease, reverse transcriptase, and integrase inhibitors by next-generation sequencing in HIV-positive patients.
    Tekin D; Gokengin D; Onay H; Erensoy S; Sertoz R
    J Med Virol; 2021 Jun; 93(6):3627-3633. PubMed ID: 33026651
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of 454 Ultra-Deep Sequencing and Allele-Specific Real-Time PCR with Regard to the Detection of Emerging Drug-Resistant Minor HIV-1 Variants after Antiretroviral Prophylaxis for Vertical Transmission.
    Hauser A; Kuecherer C; Kunz A; Dabrowski PW; Radonić A; Nitsche A; Theuring S; Bannert N; Sewangi J; Mbezi P; Dugange F; Harms G; Meixenberger K
    PLoS One; 2015; 10(10):e0140809. PubMed ID: 26469189
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Performance comparison of deep sequencing platforms for detecting HIV-1 variants in the pol gene.
    Nicot F; Jeanne N; Raymond S; Delfour O; Carcenac R; Lefebvre C; Sauné K; Delobel P; Izopet J
    J Med Virol; 2018 Sep; 90(9):1486-1492. PubMed ID: 29750364
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Performance of the Applied Biosystems HIV-1 Genotyping Kit with Integrase.
    Moore HP; Palumbo PJ; Notarte KI; Fogel JM; Cummings V; Gamble T; Del Rio C; Batey DS; Mayer KH; Farley JE; Remien RH; Beyrer C; Hudelson SE; Eshleman SH;
    J Clin Microbiol; 2024 Jun; 62(6):e0013624. PubMed ID: 38727213
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Positive selection detection in 40,000 human immunodeficiency virus (HIV) type 1 sequences automatically identifies drug resistance and positive fitness mutations in HIV protease and reverse transcriptase.
    Chen L; Perlina A; Lee CJ
    J Virol; 2004 Apr; 78(7):3722-32. PubMed ID: 15016892
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Contribution of human immunodeficiency virus type 1 minority variants to reduced drug susceptibility in patients on an integrase strand transfer inhibitor-based therapy.
    Gibson RM; Weber J; Winner D; Miller MD; Quiñones-Mateu ME
    PLoS One; 2014; 9(8):e104512. PubMed ID: 25110880
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prevalence of transmitted HIV drug resistance in Iran between 2010 and 2011.
    Jahanbakhsh F; Hattori J; Matsuda M; Ibe S; Monavari SH; Memarnejadian A; Aghasadeghi MR; Mostafavi E; Mohraz M; Jabbari H; Kamali K; Keyvani H; Azadmanesh K; Sugiura W
    PLoS One; 2013; 8(4):e61864. PubMed ID: 23626742
    [TBL] [Abstract][Full Text] [Related]  

  • 19. HIV-1 drug resistance mutations detection and HIV-1 subtype G report by using next-generation sequencing platform.
    Gholami M; Rouzbahani N; Samiee S; Tayeri K; Ghorban K; Dehkharghani AD; Gholami AA; Moshiri F; Sattari A; Dadmanesh M; Mohraz M
    Microb Pathog; 2020 Sep; 146():104221. PubMed ID: 32360523
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of GS Junior and MiSeq next-generation sequencing technologies as an alternative to Trugene population sequencing in the clinical HIV laboratory.
    Ram D; Leshkowitz D; Gonzalez D; Forer R; Levy I; Chowers M; Lorber M; Hindiyeh M; Mendelson E; Mor O
    J Virol Methods; 2015 Feb; 212():12-6. PubMed ID: 25445792
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.